Because uncontrolled growth of blood vessels (angiogenesis) contributes to the progression of diverse diseases from cancer to macular degeneration, drugs targeting the neovasculature are obvious candidates to control unwanted vascularization and tumor growth. However, most anti-angiogenic drugs must be taken up into the target cell in order to exert their effects. The availability of a potent drug that tackles angiogenesis via a different mode presents a valuable therapeutic strategy for diseases that depend on abnormal neovasculature.
University researchers have synthesized a novel lipopeptide, Somocystinamide A (ScA), which is a synthetic version of a compound isolated from marine cyanobacteria. ScA is distinguished by a lipophilic structure similar to native membrane components and this unique structure enables ScA to directly integrate into cellular membranes, perturb normal lipid homeostasis and selectively activate caspase 8, leading to programmed cell death.
The promise of anti-angiogenic drugs in is reflected in the plethora of clinical trials. The obvious applications are reflected in the distribution of ~3000 human anti-angiogenesis trials:
~85% are designed to treat various forms of cancer and
~10% are for macular degeneration and a other eye diseases (e.g., choroid & retinal diseases)
Advantages of ScA include:
ScA has been incorporated into stable, liposomal nanoparticles of 100 nM in size, which retain full potency and excellent activity in vitro and in vivo. In vivo, ScA blocks endothelial cell tube formation and developmental angiogenesis in zebrafish models.
Patent pending; publication number: US20100266675
|United States Of America||Issued Patent||9,045,401||06/02/2015||2007-225|
Somocystinamide A, anti-angiogenesis, apoptosis, anti-cancer drug, cancer, inflammatory diseases, eye disease, age related macular degeneration, combination therapy